A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes. We classify our products into three product categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Our Radiopharmaceutical Oncology product helps healthcare professionals (“HCPs”) Find, Fight and Follow cancer. Our Precision Diagnostic products assist HCPs to Find and Follow diseases. Our Strategic Partnerships include biomarkers and digital solutions in support of our partners’ therapeutic development, out-licensing agreements for non-core assets and optimization of our assets geographically, and contract development and manufacturing organization (“CDMO”) revenue generated by Evergreen.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 1.5B | 1.5B | 1.5B | 1.3B | 935M | 425M |
| Net Income | 234M | 234M | 312M | 327M | 28M | -71M |
| EPS | $3.41 | $3.41 | $4.36 | $4.65 | $0.40 | $-1.06 |
| Free Cash Flow | 354M | 354M | 493M | 260M | 22M | 42M |
| ROIC | 17.1% | 22.1% | 45.3% | 44.2% | 6.3% | -10.6% |
| Gross Margin | 61.1% | 61.1% | 64.4% | 54.7% | 62.2% | 44.1% |
| Debt/Equity | 0.57 | 0.57 | 0.57 | 0.76 | 1.31 | 0.42 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 311M | 311M | 457M | 365M | 36M | -61M |
| Operating Margin | 20.2% | 20.2% | 29.8% | 28.1% | 3.9% | -14.3% |
| ROE | 21.4% | 21.4% | 32.8% | 51.7% | 6.2% | -14.6% |
| Shares Outstanding | 68M | 68M | 72M | 70M | 70M | 67M |
Lantheus Holdings, Inc. passes 8 of 9 quality checks, indicating strong fundamentals.
Lantheus Holdings, Inc. trades at 24.0x trailing earnings, compared to its 15-year median P/E of 14.6x, suggesting it is currently Expensive relative to its historical range. On a free-cash-flow basis, the stock trades at 13.6x vs a median of 14.2x. The company's 5-year average ROIC is 21.5% with a gross margin of 57.3%. Total shareholder yield (buybacks) is 5.4%. At current prices, the estimated annualized return to fair value is +39.4%.
Lantheus Holdings, Inc. (LNTH) has a current P/E ratio of 24.0, compared to its historical median P/E of 14.6. The stock is currently considered Expensive based on its historical valuation range.
Lantheus Holdings, Inc. (LNTH) has a 5-year average return on invested capital (ROIC) of 21.5%. This indicates strong capital allocation and a potential competitive advantage.
Lantheus Holdings, Inc. (LNTH) has a market capitalization of $5.6B. It is classified as a mid-cap stock.
Lantheus Holdings, Inc. (LNTH) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 5.36%.
Based on historical P/E analysis, Lantheus Holdings, Inc. (LNTH) appears expensive. The current P/E of 24.0 is 64% above its historical median of 14.6. The estimated fair value CAGR (P/E method) is 32.3%.
Lantheus Holdings, Inc. (LNTH) operates in the In Vitro & In Vivo Diagnostic Substances industry, within the Healthcare sector.
Lantheus Holdings, Inc. (LNTH) reported annual revenue of $1.5 billion in its most recent fiscal year, based on SEC EDGAR filings.
Lantheus Holdings, Inc. (LNTH) has a net profit margin of 15.2%. This is a healthy margin.
Lantheus Holdings, Inc. (LNTH) generated $354 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Lantheus Holdings, Inc. (LNTH) has a debt-to-equity ratio of 0.57. This indicates moderate leverage.
Lantheus Holdings, Inc. (LNTH) reported earnings per share (EPS) of $3.41 in its most recent fiscal year.
Lantheus Holdings, Inc. (LNTH) has a return on equity (ROE) of 21.4%. This indicates the company generates strong returns for shareholders.
Lantheus Holdings, Inc. (LNTH) has a 5-year average gross margin of 57.3%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 13 years of financial data for Lantheus Holdings, Inc. (LNTH), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Lantheus Holdings, Inc. (LNTH) has a book value per share of $15.91, based on its most recent annual SEC filing.